Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME).
male breast cancer
metastatic breast cancer
real-life study
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
04
2020
accepted:
17
11
2020
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
26
1
2021
Statut:
epublish
Résumé
Because of its low prevalence, metastatic breast cancer (MBC) in males is managed based on clinical experience with women. Using a real-life database, we aim to provide a comprehensive analysis of male MBC characteristics, management and outcome. The Epidemiological Strategy and Medical Economics Data Platform collected data for all men and women ⩾18 years with MBC in 18 participating French Comprehensive Cancer Centers from January 2008 to November 2016. Demographic, clinical, and pathological characteristics were retrieved, as was treatment modality. Men were matched 1:1 to women with similar characteristics. Of 16,701 evaluable patients, 149 (0.89%) men were identified. These men were older (median age 69 years) and predominantly had hormone receptor HR+/HER2- disease (78.3%). Median overall survival (OS) was 41.8 months [95% confidence interval (CI: 26.9-49.7)] and similar to women. Median progression-free survival (PFS) with first-line therapy was 9.3 months [95% CI (7.4-11.5)]. In the HR+/HER2- subpopulation, endocrine therapy (ET) alone was the frontline treatment for 43% of patients, including antiestrogens ( MBC management in men and women leads to similar outcomes, especially in HR+/HER2- patients for whom ET should also be a cornerstone. Unsolved questions remain and successfully recruiting trials for men are still lacking.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Because of its low prevalence, metastatic breast cancer (MBC) in males is managed based on clinical experience with women. Using a real-life database, we aim to provide a comprehensive analysis of male MBC characteristics, management and outcome.
METHODS
METHODS
The Epidemiological Strategy and Medical Economics Data Platform collected data for all men and women ⩾18 years with MBC in 18 participating French Comprehensive Cancer Centers from January 2008 to November 2016. Demographic, clinical, and pathological characteristics were retrieved, as was treatment modality. Men were matched 1:1 to women with similar characteristics.
RESULTS
RESULTS
Of 16,701 evaluable patients, 149 (0.89%) men were identified. These men were older (median age 69 years) and predominantly had hormone receptor HR+/HER2- disease (78.3%). Median overall survival (OS) was 41.8 months [95% confidence interval (CI: 26.9-49.7)] and similar to women. Median progression-free survival (PFS) with first-line therapy was 9.3 months [95% CI (7.4-11.5)]. In the HR+/HER2- subpopulation, endocrine therapy (ET) alone was the frontline treatment for 43% of patients, including antiestrogens (
CONCLUSION
CONCLUSIONS
MBC management in men and women leads to similar outcomes, especially in HR+/HER2- patients for whom ET should also be a cornerstone. Unsolved questions remain and successfully recruiting trials for men are still lacking.
Identifiants
pubmed: 33488779
doi: 10.1177/1758835920980548
pii: 10.1177_1758835920980548
pmc: PMC7768846
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835920980548Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Clin Breast Cancer. 2014 Feb;14(1):31-9
pubmed: 24220158
Br J Cancer. 2019 Feb;120(3):301-305
pubmed: 30655614
J Exp Clin Cancer Res. 2015 Mar 21;34:26
pubmed: 25888204
Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):2-10
pubmed: 26537534
Clin Cancer Res. 2020 Mar 15;26(6):1208-1212
pubmed: 31649043
J Hematol Oncol. 2015 May 17;8:53
pubmed: 25980944
Am J Clin Oncol. 2002 Jun;25(3):235-7
pubmed: 12040279
Breast. 2017 Aug;34:115-121
pubmed: 28577471
Br J Cancer. 2013 Jun 11;108(11):2259-63
pubmed: 23722469
Ther Adv Med Oncol. 2019 Nov 16;11:1758835919889003
pubmed: 31798694
Br J Cancer. 2014 Dec 9;111(12):2351-60
pubmed: 25490678
Clin Cancer Res. 2016 Aug 15;22(16):4045-56
pubmed: 26960396
Eur J Cancer. 2017 Sep;82:219-227
pubmed: 28292559
Breast Cancer Res Treat. 2013 Aug;141(1):119-23
pubmed: 23982884
J Clin Endocrinol Metab. 2000 Jul;85(7):2370-7
pubmed: 10902781
Clin Breast Cancer. 2018 Feb;18(1):e97-e105
pubmed: 28888581
Ann Oncol. 2018 Feb 1;29(2):405-417
pubmed: 29092024
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
Ann Oncol. 2010 Jun;21(6):1243-1245
pubmed: 19861576
JNCI Cancer Spectr. 2018 Jun 01;2(2):pky018
pubmed: 31360850
Breast Care (Basel). 2014 Apr;9(4):267-71
pubmed: 25404886
J Clin Endocrinol Metab. 1974 Mar;38(3):476-9
pubmed: 4815174